What Happens If You Stop Finasteride for Hair Loss?

What happens if you stop finasteride for hair loss? Its benefit usually fades, and male pattern hair loss starts progressing again. The current UK label says reversal may begin by six months and reach baseline by 9 to 12 months. The US label says the effect reverses within 12 months. That is loss of maintenance, not proof of a special withdrawal shed. Discuss any planned change with your prescriber.

What happens if you stop finasteride?

Finasteride doesn't cure androgenetic alopecia. It blocks type II 5-alpha-reductase, which lowers production of dihydrotestosterone, or DHT. This can slow follicle miniaturisation while treatment continues. When the drug effect ends, the underlying condition is no longer being suppressed.

A label check on 27 October 2026 confirms the scope here. Organon's US prescribing information describes Propecia as a prescription oral tablet containing 1 mg of finasteride. Amarox Limited's UK product record describes the same active ingredient and tablet strength. This evidence concerns oral finasteride for male pattern hair loss. It doesn't set a stopping timeline for compounded topical finasteride or the 5 mg prostate product.

Hormones change first; visible hair changes take longer

Gormley and colleagues ran a short, blinded, placebo-controlled study in healthy men. Their 1990 paper in The Journal of Clinical Endocrinology & Metabolism tested several oral doses, including 1 mg, for 11 or 14 days. Blood DHT returned to its starting level within 14 days after the drug stopped.

That finding is biochemical. It doesn't mean your hair returns to baseline in two weeks. Scalp hairs move through long growth and resting phases, so a follicle-level change takes months to become visible.

The UK product record gives the clearest practical window. It says benefit begins to reverse by about six months and returns to baseline by 9 to 12 months. The US prescribing information uses the broader phrase “within 12 months.” These are population estimates, not a countdown for every scalp.

What the withdrawal trial actually found

Kaufman and colleagues reported two randomised trials in 1998. They enrolled 1,553 men aged 18 to 41 with male pattern hair loss. Another 1,215 entered a second blinded year. Hair counts, photographs, clinician ratings and participant reports all favoured finasteride over placebo at one and two years.

The US label also reports what happened to a group that stopped. Sixty-five men took finasteride for 12 months, then switched to placebo. Researchers had usable hair counts for 48 men. Their average increase in the measured scalp area had reversed 12 months after the switch.

This is the strongest direct evidence, but it has limits. The stopping group was small. The trials mainly studied mild-to-moderate crown loss in younger men. They didn't establish whether the drug works at receding temples. Several authors worked for Merck, and the withdrawal analysis appears in the manufacturer label. The results are group averages, not a personal schedule.

In short, the benefit wears off. The data don't show a distinct rebound that makes hair loss permanently worse than its untreated course. The change may still look sudden because several months of loss can become visible around the same time.

A decision table before changing treatment

What different stopping situations change

Situation	What the evidence says	Useful next step	Limit
No visible change after three to five months	Labels allow three to six months before stabilisation is expected. Trial gains continued beyond that point.	Ask the prescriber to check the diagnosis, adherence and comparable photos before judging failure.	No response is guaranteed, and temple evidence is weaker.
Good result, but cost or inconvenience makes you want to stop	Maintenance benefit usually fades over the following 6 to 12 months.	Discuss the trade-off and any replacement plan before creating a long gap.	No alternative is proven to preserve every finasteride-maintained hair.
New sexual symptom	Reduced libido, erection problems and ejaculation changes are recognised adverse effects.	Contact the prescriber and record the symptom, start date, severity and other medicine changes.	A symptom's timing alone cannot prove its cause.
Depression or suicidal thoughts	The UK MHRA issued specific urgent advice in May 2026 for the 1 mg hair-loss product.	Follow the regulator's instructions and seek medical help promptly. Use emergency services if there is immediate danger.	Advice and emergency routes differ by country.
Sudden patches, scalp pain, redness or heavy diffuse shedding	That pattern falls outside the gradual loss studied in finasteride trials.	Get a dermatologist or GP assessment rather than assuming this is finasteride withdrawal.	A photo cannot identify the medical cause.

Side effects may not follow the hair timeline

The current US label combines three one-year trials. One or more drug-related sexual effects were reported by 3.8% of 945 men taking finasteride. The rate was 2.1% among 934 men taking placebo. Lower libido, erectile dysfunction and ejaculation disorder each occurred in at least 1% of the finasteride group.

Mella and colleagues pooled 12 randomised trials with 3,927 men in 2010. They judged the evidence moderate quality. Erectile dysfunction was more common with finasteride, with a relative risk of 2.22. Their estimate equated to one extra case for about every 82 treated men, but the confidence interval ranged from 56 to 231.

Trial symptoms resolved after discontinuation in many men, and some resolved during continued treatment. Persistent sexual symptoms have also been reported after stopping. Spontaneous reports cannot supply a reliable frequency or prove the cause in one person.

The MHRA reviewed those uncertainties and strengthened UK warnings in 2026. It says sexual dysfunction may persist and tells patients to contact a clinician about it. Its guidance also links finasteride with depression and suicidal thoughts. UK patients taking 1 mg are told to stop and contact their doctor promptly if those psychiatric symptoms develop.

Seek urgent care for swelling of the lips, tongue, throat or face. Report breast lumps, pain or nipple discharge to a clinician. Finasteride is contraindicated in pregnancy, and pregnant people should not handle broken or crushed tablets.

If you plan to stop, decide what outcome matters

If your priority is keeping current density, stopping without another plan carries a predictable trade-off. Read why timing can affect hair-loss treatment results before assuming lost density will be easy to recover.

Olsen and colleagues tested 5% and 2% topical minoxidil against placebo in a 48-week randomised trial of 393 men. The 5% solution produced 45% more regrowth than 2% and beat placebo on each efficacy measure. That industry-funded trial involved men with vertex-pattern loss and did not test switching from finasteride. If your clinician raises minoxidil, the evidence-based minoxidil timeline explains when results and early shedding may appear.

Don't improvise a taper, intermittent schedule or dose change from internet anecdotes. Trials did not establish a universal “safe break.” A missed tablet and a planned multi-month stop are different questions. Use the instructions supplied with your product and ask the prescriber about longer interruptions.

Track the change without fooling yourself

Daily mirror checks are noisy. Light, wetness, hair length, styling and camera angle can change how much scalp shows. Compare monthly photos taken with the same camera, distance, lighting, part and dry-hair state.

If the concern is a visible front hairline change, try the photo-based hairline pattern check as a baseline. It estimates visible signals in one image. It cannot diagnose androgenetic alopecia, measure DHT, prove treatment worked or tell you whether to stop a prescription.

Bring the exact product, last-dose date, symptom timeline and comparable photos to the appointment. That record helps the clinician separate fading treatment benefit from a new cause of shedding.